1
|
Weerasuriya W, Saunders JE, Kis L, Ho TT, Xu K, Lemas DJ, Groer MW, Louis-Jacques AF. Maternal Gut Microbiota in the Postpartum Period: A Systematic Review. Eur J Obstet Gynecol Reprod Biol 2023; 285:130-147. [PMID: 37116306 DOI: 10.1016/j.ejogrb.2023.03.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Revised: 03/26/2023] [Accepted: 03/31/2023] [Indexed: 04/03/2023]
Abstract
Studies have demonstrated the importance of the gut microbiota during pregnancy, and there is emerging literature on the postpartum maternal gut microbiota. The primary objective of this paper was to synthesize the literature on the postpartum gut microbiome composition and diversity measured in stool samples from healthy mothers of predominantly term infants. The secondary objectives were (1) to identify biological and environmental factors that influence postpartum maternal gut microbiota and (2) to assess health conditions and clinical intermediate measures associated with postpartum gut microbiota changes in all mothers. Electronic searches were conducted November 9, 2020 and updated July 25, 2021 without publication time limits on PubMed, Embase, CINHAL, Scopus, Cochrane Library, BioArchives, and OpenGrey.eu. Primary research on maternal gut microbiota in the postpartum (up to one year after childbirth) were eligible. Postpartum gut microbiota comparisons to pregnancy or non-pregnancy gut microbiota were of interest, therefore, studies examining these in addition to the postpartum were included. Studies were excluded if they were only conducted in animals, infants, pregnancy, or microbiome of other body locations (e.g., vaginal). Data extraction of microbial composition and diversity were completed and synthesized narratively. Studies were assessed for risk of bias. A total of 2512 articles were screened after deduplication and 27 were included in this review. Of the 27 included studies, 22 addressed the primary objective. Firmicutes was the predominant phylum in the early (<6 weeks) and late postpartum (6 weeks to 1 year). In early postpartum, Bacteroides was the predominant genus. Findings from longitudinal assessments of alpha and beta diversity from the early to the late postpartum varied. Nineteen of the 27 studies assessed biological and environmental factors influencing the postpartum gut microbial profile changes. Timing of delivery, probiotic supplementation, triclosan exposure, and certain diets influenced the postpartum gut microbiota. Regarding health conditions and intermediate clinical measures assessed in 8 studies; inflammatory bowel disease, postpartum depression, early-onset preeclampsia, gestational diabetes, excessive gestational weight gain, and anthropometric measures such as body mass index and waist-to-hip ratio were related to gut microbiota changes. There is limited data on the maternal postpartum gut microbiota and how it influences maternal health. We need to understand the postpartum maternal gut microbiome, establish how it differs from non-pregnancy and pregnancy states, and determine biological and environmental influencers. Future research of the gut microbiome's significance for the birthing parent in the postpartum could lead to a new understanding of how to improve maternal short and long-term health.
Collapse
|
2
|
Ortiz –Villalón C, De Petris L, Kis L, Yoshikawa A, Ngoc H, Roden A, Fukuoka J, Montero A. P3.09-05 Significance of the Expression of PD-L1/PD-1 by Tumoral and Immune Cells in Non-Small Cell Lung Cancer. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1774] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
3
|
Helgadottir H, Kis L, Ljungman P, Larkin J, Kefford R, Ascierto PA, Hansson J, Masucci G. Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma. Ann Oncol 2018; 28:1672-1673. [PMID: 28407116 DOI: 10.1093/annonc/mdx177] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2017] [Indexed: 01/12/2023] Open
Affiliation(s)
- H Helgadottir
- Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital
| | - L Kis
- Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital
| | - P Ljungman
- Departments of Allogeneic Stem Cell Transplantation and Hematology, Karolinska University Hospital.,Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden
| | - J Larkin
- Melanoma Unit, Royal Marsden NHS Foundation Trust, London.,Royal Marsden Hospital, London, UK
| | - R Kefford
- Westmead Hospital, Melanoma Institute Australia and Macquarie University, Sydney, Australia
| | - P A Ascierto
- Melanoma, Cancer Immunotherapy and Innovative Therapies Unit, Istituto Nazionale Tumori di Napoli Fondazione "G. Pascale", Naples, Italy
| | - J Hansson
- Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital
| | - G Masucci
- Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital
| |
Collapse
|
4
|
Ortiz –Villalón C, Yoshikawa A, Kis L, Montero A, Roden A, Pham H, Fernandez C, Fukuoka J, Lewensohn R, De Petris L. P2.02-042 Clinical Significance of the Tumor Expression of PD-L1 Using Four Immunohistochemistry Assays in Non-Small Cell Lung Cancer. Multicentre Study. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
5
|
Atsaves V, Tsesmetzis N, Chioureas D, Kis L, Leventaki V, Drakos E, Panaretakis T, Grander D, Medeiros LJ, Young KH, Rassidakis GZ. PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. Leukemia 2017; 31:1633-1637. [PMID: 28344319 DOI: 10.1038/leu.2017.103] [Citation(s) in RCA: 128] [Impact Index Per Article: 18.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Affiliation(s)
- V Atsaves
- Department of Oncology and Pathology, Cancer Centrum Karolinska, Karolinska Institutet, Stockholm, Sweden
| | - N Tsesmetzis
- Department of Oncology and Pathology, Cancer Centrum Karolinska, Karolinska Institutet, Stockholm, Sweden
| | - D Chioureas
- Department of Oncology and Pathology, Cancer Centrum Karolinska, Karolinska Institutet, Stockholm, Sweden
| | - L Kis
- Department of Oncology and Pathology, Cancer Centrum Karolinska, Karolinska Institutet, Stockholm, Sweden.,Department of Pathology and Cytology, Karolinska University Hospital, Stockholm, Sweden
| | - V Leventaki
- Department of Pathology, St Jude Children's Research Hospital, Memphis, TN USA
| | - E Drakos
- Department of Pathology, University of Crete Medical School, Heraklion Crete, Greece
| | - T Panaretakis
- Department of Oncology and Pathology, Cancer Centrum Karolinska, Karolinska Institutet, Stockholm, Sweden
| | - D Grander
- Department of Oncology and Pathology, Cancer Centrum Karolinska, Karolinska Institutet, Stockholm, Sweden
| | - L J Medeiros
- Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
| | - K H Young
- Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
| | - G Z Rassidakis
- Department of Oncology and Pathology, Cancer Centrum Karolinska, Karolinska Institutet, Stockholm, Sweden.,Department of Pathology and Cytology, Karolinska University Hospital, Stockholm, Sweden.,Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
| |
Collapse
|
6
|
Feeney JM, Neulander M, DiFiori M, Kis L, Shapiro DS, Jayaraman V, Marshall WT, Montgomery SC. Direct oral anticoagulants compared with warfarin in patients with severe blunt trauma. Injury 2017; 48:47-50. [PMID: 27582383 DOI: 10.1016/j.injury.2016.08.016] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/30/2016] [Revised: 07/25/2016] [Accepted: 08/26/2016] [Indexed: 02/02/2023]
Abstract
METHODS We queried our Trauma Quality Improvement Program registry for patients who presented between 6/1/2011 and 9/1/2015 with severe (injury severity score (ISS)>15) blunt traumatic injury during anticoagulant use. Patients were then grouped into those prescribed warfarin and patients prescribed any of the available novel Direct Oral Anticoagulants (DOAC) medications. We excluded severe (AIS≧4) head injuries. RESULTS There were no differences between DOAC and warfarin groups in terms of age, gender mean ISS, median hospital or intensive care unit lengths of stay, complication proportions, numbers of complications per patient, or the proportion of patients requiring transfusion. Finally, excluding patients who died, the observed proportion of discharge to skilled nursing facility was similar. In our sample of trauma patients, DOAC use was associated with significantly lower mortality (DOAC group 8.3% vs. warfarin group 29.5%, p<0.015). The ratio of units transfused per patient was also lower in the DOAC group (2.8±1.8 units/patient in the DOAC group vs. 6.7±6.4 units per patient in the warfarin group; p=0.001). CONCLUSION In conclusion, we report an association with decrease in mortality and a decrease in transfused blood products in severely injured trauma patients with likely minimal or no head injury taking novel DOACs over those anticoagulated with warfarin for outpatient anticoagulation.
Collapse
Affiliation(s)
- James M Feeney
- Saint Francis Hospital and Medical Center, Department of Surgery, 114 Woodland St. Hartford, CT 06103, USA; University of Connecticut School of Medicine, 263 Farmington Ave., Farmington, CT 06030, USA.
| | - Matthew Neulander
- Saint Francis Hospital and Medical Center, Department of Emergency Medicine, 114 Woodland St. Hartford, CT 06103, USA; University of Connecticut School of Medicine, 263 Farmington Ave., Farmington, CT 06030, USA
| | - Monica DiFiori
- Trinity College, 300 Summit Street, Hartford, CT 06106, USA
| | - Lilla Kis
- Trinity College, 300 Summit Street, Hartford, CT 06106, USA
| | - David S Shapiro
- Saint Francis Hospital and Medical Center, Department of Surgery, 114 Woodland St. Hartford, CT 06103, USA; University of Connecticut School of Medicine, 263 Farmington Ave., Farmington, CT 06030, USA
| | - Vijay Jayaraman
- Saint Francis Hospital and Medical Center, Department of Surgery, 114 Woodland St. Hartford, CT 06103, USA; University of Connecticut School of Medicine, 263 Farmington Ave., Farmington, CT 06030, USA
| | - William T Marshall
- Saint Francis Hospital and Medical Center, Department of Surgery, 114 Woodland St. Hartford, CT 06103, USA; University of Connecticut School of Medicine, 263 Farmington Ave., Farmington, CT 06030, USA
| | - Stephanie C Montgomery
- Saint Francis Hospital and Medical Center, Department of Surgery, 114 Woodland St. Hartford, CT 06103, USA; University of Connecticut School of Medicine, 263 Farmington Ave., Farmington, CT 06030, USA
| |
Collapse
|
7
|
Ma L, Maruwge W, Strambi A, D'Arcy P, Pellegrini P, Kis L, de Milito A, Lain S, Brodin B. SIRT1 and SIRT2 inhibition impairs pediatric soft tissue sarcoma growth. Cell Death Dis 2014; 5:e1483. [PMID: 25341037 PMCID: PMC4237232 DOI: 10.1038/cddis.2014.385] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2014] [Revised: 08/05/2014] [Accepted: 08/07/2014] [Indexed: 11/29/2022]
Abstract
Sirtuins are NAD+ dependent deacetylases and/or ADP-ribosyl transferases active on histone and non-histone substrates. The first sirtuin was discovered as a transcriptional repressor of the mating-type-loci (Silent Information Regulator sir2) in the budding yeast, where it was shown to extend yeast lifespan. Seven mammalian sirtuins (SIRT1-7) have been now identified with distinct subcellular localization, enzymatic activities and substrates. These enzymes regulate cellular processes such as metabolism, cell survival, differentiation, DNA repair and they are implicated in the pathogenesis of solid tumors and leukemias. The purpose of the present study was to investigate the role of sirtuin expression, activity and inhibition in the survival of pediatric sarcoma cell lines.We have analyzed the expression of SIRT1 and SIRT2 in a series of pediatric sarcoma tumor cell lines and normal cells, and we have evaluated the activity of the sirtuin inhibitor and p53 activator tenovin-6 (Tv6) in synovial sarcoma and rhabdomyosarcoma cell lines. We show that SIRT1 is overexpressed in synovial sarcoma biopsies and cell lines in comparison with normal mesenchymal cells. Tv6 induced apoptosis as well as impaired autophagy flux. Using siRNA to knock down SIRT1 and SIRT2, we show that the expression of both proteins is crucial for the survival of rhabdomyosarcoma cells and that the loss of SIRT1 expression results in a decreased LC3II expression. Our results show that SIRT1 and SIRT2 expressions are crucial for the survival of synovial sarcomas and rhabdomyosarcomas, and demonstrate that the pharmacological inhibition of sirtuins impairs the autophagy process and induces tumor cell death.
Collapse
Affiliation(s)
- L Ma
- Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
| | - W Maruwge
- Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
| | - A Strambi
- Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
| | - P D'Arcy
- Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
| | - P Pellegrini
- Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
| | - L Kis
- Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
| | - A de Milito
- Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
| | - S Lain
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
| | - B Brodin
- Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
| |
Collapse
|
8
|
Sebestyén A, Hajdu M, Kis L, Barna G, Kopper L. Smad4-independent, PP2A-dependent apoptotic effect of exogenous transforming growth factor beta 1 in lymphoma cells. Exp Cell Res 2007; 313:3167-74. [PMID: 17643425 DOI: 10.1016/j.yexcr.2007.05.028] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2006] [Revised: 04/10/2007] [Accepted: 05/30/2007] [Indexed: 11/20/2022]
Abstract
B-lymphoid tumor cells are often less sensitive than their normal counterparts or insensitive to transforming growth factor beta1 (TGFb) effects. We studied the apoptotic effect of exogenous TGFb in B-lymphoma cells, focusing on the activity and the role of Smad and protein phosphatase/kinase signals. Recombinant TGFb treatment and Smad4 siRNA transfection were used in HT58 B-NHL lymphoma cells in vitro. Gene expression and apoptosis were detected by RT-PCR, Western blot analysis and flow cytometry. The role of MEK1 kinase and PP2A activity--measured with a phosphatase assay--were assessed with the help of specific inhibitors. Smad4 siRNA treatment completely abolished TGFb-induced early gene upregulation, indicating the absence of the rapid activation of Smad signaling. Moreover, functional inhibition of Smad4 had no influence on TGFb-induced apoptosis, but it was dependent on PP2A phosphatase activation, ERK1/2 and JNK inactivation in lymphoma cells. The results prove that exogenous TGFb uses Smad4-independent, alternative (PP2A/PP2A-like dependent) signaling pathways for apoptosis induction in lymphoma cells. Further studies are needed to clarify the possible role and involvement of Smad4-independent effects of TGFb in normal and malignant lymphoid cells and in cells of the tumor microenvironment.
Collapse
Affiliation(s)
- Anna Sebestyén
- Semmelweis University, I. Department of Pathology and Experimental Cancer Research, 1085 Budapest, Ulloi út 26, Hungary.
| | | | | | | | | |
Collapse
|
9
|
Kis L, Pfaffenberger M. [Painless jaundice after ecstasy and alcohol consumption]. Praxis (Bern 1994) 2007; 96:1035-7. [PMID: 17639967 DOI: 10.1024/1661-8157.96.25.1035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
Ein 21-jähriger Patient wurde uns vom Hausarzt wegen seit einer Woche bestehendem Ikterus mit dunklem Urin zugewiesen. Im Labor wurde eine 50fache Erhöhung der Transaminasen bei gleichzeitiger Bilirubinurie, ausgeprägter Cholestase und leicht vermindertem INR von 1,2 (Quick 64%) festgestellt. Eine virale, autoimmunologisch bedingte Hepatitis oder hereditäre Hämochromatose konnte serologisch ausgeschlossen werden. Die Abdomensonographie fiel bis auf eine leichte Hepatomegalie, ohne Anhaltspunkte für intra- oder extrahepatische Cholestase, unauffällig aus. Die Leberbiopsie zeigte eine subakute Hepatitis mit Leberzellnekrose. Anamnestisch war dem Ikterus ein Alkoholkonsum unter gleichzeitiger, erstmaliger Einnahme von Ecstasy vorausgegangen. Es wurde die Diagnose einer Ecstasy- und Alkohol-induzierten schweren nekrotisierenden Hepatitis gestellt. Nach 14 Tagen zeichnete sich der Rückgang der Hepatitis ab mit sinkenden Leberwerten und normalem Spontan-INR. Die Leberwerte normalisierten sich schliesslich nach zwei Monaten vollständig.
Collapse
Affiliation(s)
- L Kis
- Medizinische Klinik, Kantonales Spital Sursee-Wolhusen KSSW.
| | | |
Collapse
|
10
|
Kis L, Heitzmann F, Keusch G, Möddel M. [Severe anemia in the framework of zidovudine treatment in HIV disease]. Praxis (Bern 1994) 2006; 95:119-22. [PMID: 16485608 DOI: 10.1024/0369-8394.95.4.119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
Eine 34-jährige Patientin mit einer HIV-Erkrankung im Stadium C3 nach CDC-Klassifikation wurde uns wegen einer symptomatischen Anämie zugewiesen. Die Patientin wurde seit 18 Monaten mit einer antiretroviralen Therapie mit Nukleosidanaloga (Combivir®: Zidovudin , Lamivudin) und HIV-Protease-Inhibitoren (Kaletra®: Lopinavir, Ritonavir) behandelt. Es wurde eine schwere hypoproliferative, makrozytäre Anämie (Hämoglobin 3.0 g/dl) festgestellt. Eine Blutungsanämie und ein Eisen-, Vitamin-B12- oder Folsäuremangel wurden ausgeschlossen. Die Knochenmarksuntersuchung zeigte bei fehlenden peripheren Retikulozyten eine isoliert verminderte Erythropoese bei ansonsten unauffälligen, normalreifenden Zellreihen. Es wurde die Diagnose einer Zidovudin-induzierten Pure red cell aplasia gestellt. Nach Absetzen von Zidovudin und Umstellung der antiretroviralen Therapie erholte sich die Erythropoese mit Normalisierung des Hämoglobin.
Collapse
Affiliation(s)
- L Kis
- Medizinische Klinik, Stadtspital Waid Zürich
| | | | | | | |
Collapse
|